Inhibitory synaptic loss drives network changes in multiple sclerosis: An ex vivo to in silico translational study

Marijn Huiskamp, Svenja Kiljan, Shanna Kulik, Maarteen E Witte, Laura E Jonkman, John GJM Bol, Geert J Schenk, Hanneke E Hulst, Prejaas Tewarie, Menno M Schoonheim and Jeroen JG Geurts

Abstract

Background: Synaptic and neuronal loss contribute to network dysfunction and disability in multiple sclerosis (MS). However, it is unknown whether excitatory or inhibitory synapses and neurons are more vulnerable and how their losses impact network functioning.

Objective: To quantify excitatory and inhibitory synapses and neurons and to investigate how synaptic loss affects network functioning through computational modeling.

Methods: Using immunofluorescent staining and confocal microscopy, densities of glutamatergic and GABAergic synapses and neurons were compared between post-mortem MS and non-neurological control cases. Then, a corticothalamic biophysical model was employed to study how MS-induced excitatory and inhibitory synaptic loss affect network functioning.

Results: In layer VI of normal-appearing MS cortex, excitatory and inhibitory synaptic densities were significantly lower than controls (reductions up to 14.9%), but demyelinated cortex showed larger losses of inhibitory synapses (29%). In our computational model, reducing inhibitory synapses impacted the network most, leading to a disinhibitory increase in neuronal activity and connectivity.

Conclusion: In MS, excitatory and inhibitory synaptic losses were observed, predominantly for inhibitory synapses in demyelinated cortex. Inhibitory synaptic loss affected network functioning most, leading to increased neuronal activity and connectivity. As network disinhibition relates to cognitive impairment, inhibitory synaptic loss seems particularly relevant in MS.

Keywords: Multiple sclerosis, inhibitory synaptic loss, network function; histopathology, computational modeling

Introduction

Multiple sclerosis (MS) is a chronic inflammatory, demyelinating, and neurodegenerative disease of the central nervous system.1 In most patients, the disease progresses from an initial relapsing–remitting phase to a secondary-progressive phase characterized by gradual clinical worsening and progressive neurodegeneration.2 Two principal pathological hallmarks of this progressive phase are neuronal and synaptic loss, which are both related to clinical and cognitive functioning.3,4

Despite the frequent reports of neuronal and synaptic loss in MS, a hitherto undecided debate concerns the question whether excitatory or, rather, inhibitory neurons and synapses are more susceptible to MS pathology. Whereas some studies have purported that certain types of excitatory neurons are more vulnerable in MS,5 others have argued for a selective vulnerability of inhibitory cells.6 Also regarding excitatory and inhibitory synaptic loss, no definite conclusion has been reached which type, if any, occurs more in MS. Two recent studies found loss of inhibitory, but not excitatory, synapses in post-mortem MS hippocampi.6,7 Another study, however, found equal losses of both synaptic types.8 This debate is particularly urgent as synapses form the basis for neural communication and higher order network function,
which is governed by a strict balance between excitation and inhibition.\textsuperscript{4,9} Recent work has shown that inhibitory synapses are especially important for cortical function and neural computation, despite their lower number.\textsuperscript{10} Healthy network dynamics are crucial for brain functioning and synaptic loss may perturb this, thus contributing to the network dysfunction and clinical impairment frequently seen in MS.\textsuperscript{4,11} These results warrant further quantifications of excitatory and inhibitory synaptic loss in MS, as well as investigations into the resulting effects on cortical network functioning.

Here, we aimed to achieve both these objectives. First, we determined whether excitatory or inhibitory neurons and synapses are more vulnerable to MS pathology using a large post-mortem MS dataset and detailed histopathological analysis. Second, the synaptic densities found in MS were used as input for an established corticothalamic biophysical model that accurately mimics large-scale brain networks.\textsuperscript{12,13} This allowed us to evaluate the differential and combined effects of excitatory and inhibitory synaptic loss on network functioning.

**Materials and methods**

**Subjects and tissue collection**

In this study, 33 cases with clinically definite and neuropathologically verified MS and 9 pathologically confirmed non-neurological controls (NCs) were included shortly after death. Tissue from the right superior frontal cortex was collected in a standardized manner by an experienced pathologist (supplemental methods). Tissue collection was done in collaboration with the Netherlands Brain Bank (NBB; http://www.brainbank.nl) and Normal Aging Brain Collection Amsterdam (NABCA; http://www.nabca.eu). This study complies with the institutional ethics guidelines. Subjects or their next of kin provided written informed consent for the use of their tissue and clinical information for research purposes to the NBB or NABCA.

**Histopathology**

**Staining protocol: cortical demyelination and region of interest selection.** Stainings were performed on consecutive 10-µm-thick formalin-fixed and paraffin-embedded sections. Tissue sections were stained for myelin using proteolipid protein antibody to localize demyelinated regions. For subsequent analyses, uniform (i.e. six-layered) superior frontal cortex was selected to minimize cytoarchitecture heterogeneity and to avoid over- or underestimation of pathology in sulci and gyri, respectively. Areas were classified as demyelinated when clear demyelination was visible within the area, or otherwise as normal-appearing gray matter (NAGM). These selected regions of interest (ROIs) were randomized and two regions per participant were analyzed further. All stains and quantifications described below were performed within these same areas on consecutive sections and all analyses were performed in ImageJ (version 1.52a; https://imagej.net/Fiji). For details on the staining protocol for myelin, parvalbumin- (PV\textsuperscript{+}) and calretinin-expressing (CR\textsuperscript{+}) interneurons, NeuN-expressing neurons (NeuN\textsuperscript{+}), and excitatory and inhibitory synapses, please see the supplemental methods.

**Quantification of PV\textsuperscript{+}, CR\textsuperscript{+}, and NeuN\textsuperscript{+} neurons.** Consecutive images at 20× magnification were taken with a multispectral imaging whole slide scanner ( Vectra Polaris, PerkinElmer, USA) until the entire section was imaged. The “Analyze Particles” tool was used to perform a particle count within the ROIs across all cortical layers. In case of matching tissue types in both ROIs (i.e. both contained normal-appearing or demyelinated cortex), the results of the neuron counts were averaged and converted to counts/mm\textsuperscript{2}. Outcome measures were thus densities of PV\textsuperscript{+}, CR\textsuperscript{+}, and NeuN\textsuperscript{+} neurons across all cortical layers.

**Quantification of inhibitory and excitatory synapses.** Sections of inhibitory (vGAT/gephyrin) and excitatory (vGLUT/PSD95) synapses were imaged using a confocal microscope (Nikon Instruments A1 Confocal Laser Microscope; Nikon Instruments Inc., USA). For this study, cortical layers I–III and VI were a priori included given their common demyelination in MS. Layers I–III are in close proximity to the cerebrospinal fluid (CSF) and most frequently involved in subpial lesions. Layer VI, being adjacent to the white matter (WM), is especially involved in leukocortical lesions. Therefore, images were taken in layers I–VI of the cortex at 1800× magnification. Layers were distinguished based on densities of pyramidal neurons. The “Synapse Counter” plugin was then used to determine co-localizations of pre- and post-synapses to obtain the count of “functional” synapses. Again, in case of matching tissue types in both ROIs, the synapse counts were averaged per cortical layer. Synaptic outcomes were counts/mm\textsuperscript{2} for each cortical layer (supplemental methods).
In silico analysis: corticothalamic biophysical model

In order to evaluate the effects of altered excitatory and inhibitory synaptic densities on network functioning, an established corticothalamic mean-field model was employed. This biophysical model generates time series reflecting neuronal oscillations from magnetoencephalography (MEG) registrations (supplementary methods and previous studies). Because it is one of the few biophysical models that include the thalamus, it allows the generation of realistic alpha-band oscillations (8–13 Hz) via thalamo-cortical loops. The alpha band has previously been found to show clinically relevant alterations in MS. Moreover, this model allows the modulation of synaptic densities, making it especially suited to test the loss of synapses in MS. In short, the model is built up of units, each composed of two cortical (i.e. excitatory and inhibitory) and two thalamic populations. For each unit containing these four populations, excitatory and inhibitory synaptic connections exist between populations (Figure 3(a)). We allow for communication between brain regions by connecting the excitatory cortical connections between regions. The number of regions was chosen to reflect the 78 cortical regions of the Automated Anatomical Labeling atlas, a frequently used atlas in neuroimaging, and the structural connection strength between regions was based on empirical structural tractography data (Supplemental methods).

The computational model generates oscillations for each of the 78 brain regions. Equations and values used for all settings (except for synaptic densities and number of iterations) were purposefully kept identical to previously published work, in order to specifically study the effect of synaptic loss. Hence, each “run” consisted of 50 iterations in which synaptic densities were gradually reduced. The model was used for three conditions: first, to study the effects of excitatory synaptic loss, then inhibitory synaptic loss, and finally both synaptic types concurrently. Over the iterations respective synaptic types were reduced in a step-wise manner until one region reached a reduction equal to the empirical data of the post-mortem study (Figure 3 and Supplemental methods).

Biophysical model outcome measures. Outcome measures were chosen that reflect neuronal activity and functional connectivity (FC). For neuronal activity, we calculated the mean activity, defined as the power spectral density within the alpha band. For FC, the phase locking value (PLV) was calculated. When two signals “lock” phases (i.e. their phase difference is constant), they are assumed to have high connectivity. The PLV was calculated between all region pairs resulting in a weighted connectivity matrix which was averaged to obtain a mean PLV value for each iteration of the model.

Statistical analysis. Statistical analyses were performed using IBM SPSS26 (IBM Corp., USA). Demographics and post-mortem delay were compared between MS patients and controls using chi-square and Mann–Whitney U tests.

Neuronal (i.e. PV+, CR+, and NeuN+) and synaptic (i.e. excitatory and inhibitory) densities were compared using linear mixed-effects models, to account for nested data (i.e. multiple ROIs and, for synapses, multiple cortical layers per individual). Fixed effects consisted of tissue type (i.e. NC cortex, MS NAGM, and MS demyelinated cortex) and, for synapses, cortical layer (i.e. I–VI). Analyses were controlled for age, sex, and post-mortem delay. Outcomes of interest for neurons were differences between tissue type and, for synapses, interactions between tissue type and layer. In case of significant interaction effects in the synapse analyses (i.e. p values <0.05), linear mixed-effects models were applied for each layer separately. Residuals were checked for normality.

Results

Demographics

Demographic and neuropathological data are displayed in Table 1 and Supplemental Table S1. Whereas MS and NC groups did not differ on age and sex distribution, post-mortem delay was significantly shorter in patients (p < 0.001).

Neuronal densities

Of the 42 (33 MS and 9 NC) tissue blocks, a total of 88 ROIs (71 MS, 17 NC) were analyzed. In MS tissue, 17/71 (23.9%) ROIs were demyelinated, and the remaining 54 (76.1%) were NAGM (Figure 1(a)). All NC ROIs were normal gray matter. After averaging the ROIs that were classified as the same type, a total of 9 NC, 29 MS NAGM, and 13 MS demyelinated cortex measurements were entered in the final analysis. PV+- and CR+-interneuron densities did not differ between tissue types (Figure 1(b), (d), and (e); Table S1), but NeuN+ neuronal densities did show significant differences ($F(2, 38)=4.472, p=0.018$). Post hoc tests showed NeuN+ densities to be higher in MS NAGM compared to NC ($p=0.038$) and MS demyelinated cortex ($p=0.015$; Figure 1(b) and (c)). As the
increased NeuN+ densities in MS NAGM could be caused by tissue compaction, this may have influenced the interneuron results. To minimize this effect, we repeated the interneuron analysis with NeuN+ density as covariate. This did not alter the results.

**Synaptic densities**

For both excitatory (F(6, 150.15) = 3.13, p = 0.006) and inhibitory (F(6, 152.97) = 3.68, p = 0.002) synaptic densities, a significant interaction effect was observed between tissue type and cortical layer. Post hoc analyses revealed an increased excitatory synaptic density in cortical layer I (p = 0.049) and a reduction of both synaptic types in cortical layer VI (excitatory: p = 0.004; inhibitory: p = 0.002, Figure 2, Table S2). However, after repeating this analysis with NeuN+ density as covariate to correct for potential tissue compaction, only layer VI remained significant (supplemental results). In layer VI, both synaptic types were reduced in MS NAGM and demyelinated cortex as compared to NC (excitatory: MS NAGM vs. NC: −12.5%, p = 0.003, demyelinated cortex vs. NC: −18.5%, p = 0.001; inhibitory: MS NAGM vs. NC: −14.9%, p = 0.039, demyelinated cortex vs. NC: −29.3%, p = 0.001, demyelinated cortex vs. NAGM: −14.4%, p = 0.037, Figure 2(c) and (d)). Thus, reductions in layer VI MS NAGM of excitatory and inhibitory synapses compared to NC values were similar (i.e. −12.5% and −14.9%, respectively). But, for demyelinated cortex, the reduction was significantly larger for inhibitory than for excitatory synapses (i.e. −29.3% vs. −18.5%, p = 0.047).

**Discussion**

The current study investigated whether excitatory or inhibitory neurons and synapses are more vulnerable to MS pathology and how excitatory and inhibitory synaptic loss affect network function. Post-mortem MS cortical layer VI showed reductions in both excitatory and inhibitory synaptic densities. In MS NAGM layer VI, excitatory and inhibitory synaptic losses compared to NC were −12.5% and −14.9%, respectively. In MS demyelinated cortex layer VI, inhibitory synaptic loss was more severe, as this reached levels of −29.3% versus −18.5% for excitatory synapses. In our computational model, reducing excitatory synapses led to a decrease in both neuronal activity (i.e. alpha-band spectral power) and FC (i.e. PLV), whereas reducing inhibitory synapses showed the opposite: an increase in both measures. Interestingly, when reducing both synaptic types simultaneously, a disinhibitory increase was observed in both neuronal activity and FC. Thus, despite the fact that MS affects both excitatory and inhibitory synapses, inhibitory synaptic loss was found to affect network function more severely.

This is one of the first studies translating damage at the synaptic level to macroscopic functional changes. Using histopathology and computational modeling, we show that even minor changes in synaptic density can lead to large network shifts. Computational models have the ability to connect data across levels of experimentation and the current neural mass model specifically generates whole-brain neuronal dynamics based on summed action potentials of individual neuronal populations.12,19 This particular model has been shown to accurately mimic large-scale brain dynamics and to capture pathological brain states such as MS.13,20 In addition, this model includes the thalamus, which allows the generation of corticothalamic alpha oscillations. In MS, increased alpha-band power and connectivity and corticothalamic tract damage are correlates of clinical and cognitive dysfunction, making this neural mass model the optimal choice for the current analysis.15,21 Here, we extend previous studies by feeding real-world excitatory and inhibitory synaptic densities into the model. Our results not only corroborate previous work that found inhibitory synaptic functioning to be of particular importance for
Table 1. Demographic characteristics.

|                     | NC (N=9) | MS (N=33) | p value |
|---------------------|----------|-----------|---------|
| Female (%)          | 5 (55.6) | 21 (63.6) | 0.711   |
| Age (years)         | 72 (70–77.5) | 60 (55–75.5) | 0.065 |
| Post-mortem delay (minutes) | 600 (405–700) | 315 (255–382.5) | <0.001 |

Values are presented as median (IQR) unless specified otherwise.

Figure 1. Myelin and neuronal immunohistopathological stainings and quantifications: (a) Myelin staining using PLP showing demyelinated MS cortex, (b) Stainings for NeuN-expressing neurons (NeuN$^{+}$), parvalbumin-expressing interneurons (PV$^{+}$), and calretinin-expressing interneurons (CR$^{+}$) showing all cortical layers. (c) Quantifications of neuronal types for non-neurological control cortex (NC), multiple sclerosis normal-appearing gray matter (MS NAGM), and multiple sclerosis demyelinated cortex (MS demyel. cortex) with means and 95% confidence intervals.
cortical function and cognition but they also suggest that the levels of synaptic loss seen in end-stage MS substantially perturb this dynamic.\textsuperscript{10}

The PV\textsuperscript{+} - and CR\textsuperscript{+} -interneuron densities did not differ between groups. Although some earlier studies did report loss of these neuronal types in MS, unchanged densities have also been found.\textsuperscript{5,6,22} These varying reports could be due to variations in the investigated brain regions or cortical layers, or could be due to the relatively low number of interneurons.\textsuperscript{23} By contrast, NeuN\textsuperscript{+}-expressing neuron densities were higher in

---

**Figure 2.** Immunofluorescent stainings and quantifications of inhibitory and excitatory synapses. (a) Inhibitory presynaptic vesicular GABA transporter (vGAT, in green), postsynaptic inhibitory protein gephyrin (in red), and a merged image in which yellow indicates co-localization of inhibitory pre- and postsynaptic elements. Nuclei were stained using 4',6-diamino-2-phenylindole (DAPI, in blue). (b) Excitatory presynaptic vesicular glutamate transporter (vGluT in green), postsynaptic excitatory protein PSD95 (in red), and a merged image in which yellow indicates co-localization of excitatory pre- and postsynaptic elements. (c) Quantifications of inhibitory and excitatory synaptic densities across layers I, II, III, and VI for the three tissue types.

NC: non-neurological control cortex; NAGM: multiple sclerosis normal-appearing gray matter; demyel. cortex: multiple sclerosis demyelinated cortex.
Multiple Sclerosis Journal compared to NC and MS demyelinated cortex. Despite neuronal loss being a pathological hallmark of MS, these results are not completely unexpected. Equal or even higher neuronal densities have been found previously in MS and have been explained by tissue compaction.\cite{8,24,25} In our MS NAGM sample, there may have been a limited amount of neuronal loss that hypothetically coincided with substantial tissue compaction, which may then have resulted in higher perceived neuronal densities. In MS demyelinated cortex, it could be that both neuronal loss and tissue compaction are present due to higher levels of demyelination and resulted in a net neuronal density similar to NC cortex. However, as additional measures such as glial densities were out of scope for the current study, this explanation remains tentative.

Synaptic loss was only noted in cortical layer VI, which may seem surprising as previous literature suggests that superficial layers are more affected, potentially due to meningeal infiltrates or immune mediators in the CSF.\cite{26} Cortical layer VI projects mainly to the thalamus, forming modulatory feedback loops.\cite{27} This may explain why synaptic loss was observed solely in this layer, as the thalamus shows early and severe structural disconnection and atrophy in MS.\cite{28} As a result of retrograde degeneration, it is possible that inflammation and corticothalamic

Figure 3. Overview of biophysical model and functional consequences of synaptic loss. (a) Each cortical region is composed of units consisting of neural populations with coupled excitatory (E) and inhibitory (I) cortical and thalamic reticular (R) and relay (S) components. (b) The empirically informed white matter connections are displayed. Figure was adapted from Tewarie et al.\cite{13} and Figure (a) was created with BioRender.com. (c) The effect of synaptic loss on functional connectivity (mean PLV, top row) and neuronal activity (spectral power, bottom row). Shown are the mean values over iterations (red lines) with standard deviations (gray areas). It can be appreciated that despite similar relative reductions in densities for excitatory and inhibitory synapses, damage to both synaptic types leads to an increase in both functional connectivity and neuronal activation.
disconnection induce distant synaptic loss in cortical layer VI. In MS, synapses are engulfed and stripped by microglia and macrophages. This is considered neuroprotective in the healthy brain, but is thought to go astray in MS. Increased synaptic stripping is likely caused by complement deposition in synaptic terminals, which primes the synapses for phagocytosis, and which may predominantly target inhibitory synapses. These studies, in combination with work suggesting that synaptic loss may be reversible with treatment, may provide new avenues to understand and, eventually, prevent synaptic loss in MS.

The synaptic loss and network disinhibition that were observed have clinical implications as well. MEG and functional magnetic resonance imaging (fMRI) studies have observed increased alpha power and corticothalamic connectivity in MS and found that this related to cognitive dysfunction. This suggests that the hyperconnectivity often seen in MS could be the result of inhibitory synaptic loss and implies that this is not a process of functional reorganization, but rather maladaptive disinhibition, which could also be related to epilepsy seen frequently in MS. As the thalamus is a hub in the brain network and pivotal for cognition, MS-induced thalamic atrophy and increased corticothalamic signaling may eventually lead to cognitive deterioration. However, due to our post-mortem study design, it is not yet possible to make direct generalizations to the MS population.

This work is not without limitations. First, post-mortem delay was significantly shorter in MS than in NC, whereas NCs were several years older (p=0.065). Therefore, all analyses were corrected for age and post-mortem delay. Second, in the histopathological analysis, only the right superior frontal cortex layers I–III and VI were studied. As neuronal and synaptic loss may fluctuate between brain regions, this limits the generalizability of our results. In addition, we a priori selected cortical layers I–III and VI due to their common demyelination in MS, but this does not exclude the possibility that layers IV and V have altered neuronal and synaptic densities as well. Furthermore, superior frontal cortex cytoarchitecture may have been heterogeneous and could have influenced our results. However, this was minimized by our standardized dissection protocol and by only selecting straight, uniform cortex. Next, using a z-stack in which pre- and postsynaptic co-localizations were maximum projected to obtain a two-dimensional image was suboptimal. Future studies should include more regions and use a three-dimensional slab. The neural mass model that was employed has been shown to accurately reflect healthy and pathological brain states, but cannot be said to have captured a multidimensional disease such as MS in its entirety. Here, we have deliberately chosen to only model excitatory and inhibitory synaptic loss due to relevance of these synaptic types for network functioning. But, future work should also take into account individual cortical layers, white and gray matter loss, and specifically incorporate thalamic histopathology data, which was not possible for the current study.

In conclusion, by translating from micro- to macro-scale levels of experimentation, this study shows how comparable losses of excitatory and inhibitory synapses in MS may have diverging effects on macro-scale networks. In our computational model, the loss of inhibitory synapses impacted the network more profoundly, leading to a disinhibitory increase in FC (PLV) and neuronal activity (alpha power). As both these changes in the alpha band are known to relate to cognitive impairment in MS, our results stress that inhibitory synaptic loss is of particular importance in MS-related network dysfunction.

Declaration of conflicting interests
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: M.H. receives research support from the Dutch MS Research Foundation. L.E.J. receives research support from Alzheimer Nederland, Michael J Fox Foundation, Stichting ParkinsonFonds, and Health Holland. H.E.H. receives research support from Dutch MS Research Foundation, ZonMW, NWO, ATARA, Biogen, Celgene/BMS, Merck, and MedDay; serves as a consultant for Sanofi Genzyme, Merck BV, Biogen Idec, Roche, and Novartis; and is on the editorial board of Multiple Sclerosis Journal. M.M.S. serves as an editorial board member of Frontiers in Neurology, received research support from the Dutch MS Research Foundation ARSEP, Eurostars-EUREKA, ZonMW, Amsterdam Neuroscience, Atara, Biogen, Celgene/BMS, Merck, and MedDay; and received consulting or speaking fees from ExceMed, Genzyme, Novartis, and Biogen. J.J.G.G. has served as a consultant for Merck-Serono, Biogen, Novartis, Genzyme, and Teva Pharmaceuticals; he has received research support from the Dutch MS Research Foundation, Ammodo, Eurostars-EUREKA, Biogen, Celgene/BMS, Merck, MedDay, and Novartis. Other authors report no competing interests.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or
publication of this article: This study was supported by the Dutch MS Research Foundation (grant nos. 14-358e and 16-954b), and MoveS foundation.

ORCID iDs
Marijn Huiskamp https://orcid.org/0000-0002-9471-1772
Hanneke E Hulst https://orcid.org/0000-0002-5039-1359
Menno M Schoonheim https://orcid.org/0000-0002-2504-6959

Data availability
The data analyzed in this study are available from the corresponding author on reasonable request.

Supplemental material
Supplemental material for this article is available online.

References
1. Dendrou CA, Fugger L and Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol 2015; 15: 545–558.
2. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology 2014; 83: 278–286.
3. Mandolesi G, Gentile A, Musella A, et al. Synaptopathy connects inflammation and neurodegeneration in multiple sclerosis. Nat Rev Neurol 2015; 11: 711–724.
4. Di Filippo M, Portaccio E, Mancini A, et al. Multiple sclerosis and cognition: Synaptic failure and network dysfunction. Nat Rev Neurosci 2018; 19: 599–609.
5. Schirmer L, Velmeshev D, Holmqvist S, et al. Neuronal vulnerability and multilineage diversity in multiple sclerosis. Nature 2019; 573: 75–82.
6. Zoupi L, Booker SA, Eigel D, et al. Selective vulnerability of inhibitory networks in multiple sclerosis. Acta Neuropathol 2021; 141: 415–429.
7. Ramaglia V, Dubey M, Malpede MA, et al. Complement-associated loss of CA2 inhibitory synapses in the demyelinated hippocampus impairs memory. Acta Neuropathol 2021; 142: 643–667.
8. Vercellino M, Marasciulo S, Grifoni S, et al. Acute and chronic synaptic pathology in multiple sclerosis gray matter. Mult Scler 2022; 28: 369–382.
9. Kim R and Sejnowski TJ. Strong inhibitory signaling underlies stable temporal dynamics and working memory in spiking neural networks. Nat Neurosci 2021; 24: 129–139.
10. Mongillo G, Rumpel S and Loewenstein Y. Inhibitory connectivity defines the realm of excitatory plasticity. Nat Neurosci 2018; 21: 1463–1470.
11. Stam CJ. Modern network science of neurological disorders. Nat Rev Neurosci 2014; 15: 683–695.
12. Robinson PA, Loxley PN, O’Connor SC, et al. Modal analysis of corticothalamic dynamics, electroencephalographic spectra, and evoked potentials. Phys Rev E Stat Nonlin Soft Matter Phys 2001; 63(4Pt1): 041909.
13. Tewarie P, Steenwijk MD, Brookes MJ, et al. Explaining the heterogeneity of functional connectivity findings in multiple sclerosis: an empirically informed modeling study. Hum Brain Mapp 2018; 39: 2541–2548.
14. Robinson PA, Rennie CJ and Rowe DL. Dynamics of large-scale brain activity in normal arousal states and epileptic seizures. Phys Rev E Stat Nonlin Soft Matter Phys 2002; 65(4 Pt. 1): 041924.
15. Schoonhoven DN, Fraschini M, Tewarie P, et al. Resting-state MEG measurement of functional activation as a biomarker for cognitive decline in MS. Mult Scler 2019; 25: 1896–1906.
16. Schoonheim MM, Geurts JJ, Landi D, et al. Functional connectivity changes in multiple sclerosis patients: a graph analytical study of MEG resting state data. Hum Brain Mapp 2013; 34: 52–61.
17. Lachaux JP, Rodriguez E, Martinerie J, et al. Measuring phase synchrony in brain signals. Hum Brain Mapp 1999; 8: 194–208.
18. Sorbara CD, Wagner NE, Ladwig A, et al. Pervasive axonal transport deficits in multiple sclerosis models. Neuron 2014; 84: 1183–1190.
19. Breakspear M. Dynamic models of large-scale brain activity. Nat Neurosci 2017; 20: 340–352.
20. Roberts JA and Robinson PA. Modeling absence seizure dynamics: implications for basic mechanisms and measurement of thalamocortical and corticothalamic latencies. J Theor Biol 2008; 253: 189–201.
21. Bisecco A, Rocca MA, Pagani E, et al. Connectivity-based parcellation of the thalamus in multiple sclerosis and its implications for cognitive impairment: a multicenter study. Hum Brain Mapp 2015; 36: 2809–2825.
22. Kiljan S, Prins M, Baselmans BM, et al. Enhanced GABAergic immunoreactivity in hippocampal neurons and astroglia of multiple sclerosis patients. J Neuropathol Exp Neurol 2019; 78: 480–491.
23. Aika Y, Ren JQ, Kosaka K, et al. Quantitative analysis of GABA-like-immunoreactive and parvalbumin-containing neurons in the CA1 region of
the rat hippocampus using a stereological method, the
disector. Exp Brain Res 1994; 99: 267–276.

24. Jonkman LE, Klaver R, Fleysher L, et al. The
substrate of increased cortical FA in MS: A 7T post-
mortem MRI and histopathology study. Mult Scler
2016; 22: 1804–1811.

25. Preziosa P, Kiljan S, Steenwijk MD, et al. Axonal
degeneration as substrate of fractional anisotropy
abnormalities in multiple sclerosis cortex. Brain
2019; 142: 1921–1937.

26. Pardini M, Brown JWL, Magliozi R, et al.
Surface-in pathology in multiple sclerosis: A new
view on pathogenesis? Brain J Neurol 2021; 144:
1646–1654.

27. Shepherd GMG and Yamawaki N. Untangling the
cortico-thalamo-cortical loop: Cellular pieces of a
knotty circuit puzzle. Nat Rev Neurosci 2021; 22:
389–406.

28. Azevedo CJ, Cen SY, Khadka S, et al. Thalamic
atrophy in multiple sclerosis: A magnetic resonance
imaging marker of neurodegeneration throughout
disease. Ann Neurol 2018; 83: 223–234.

29. Vercellino M, Merola A, Piacentino C, et al. Altered
glutamate reuptake in relapsing-remitting and
secondary progressive multiple sclerosis cortex:
Correlation with microglia infiltration, demyelination,
and neuronal and synaptic damage. J Neuropathol
Exp Neurol 2007; 66: 732–739.

30. Werneburg S, Jung J, Kunjamma RB, et al. Targeted
Complement Inhibition at Synapses Prevents
Microglial Synaptic Engagement and Synapse Loss in
Demyelinating Disease. Immunity 2020; 52: 167–182. e7.

31. Michailidou I, Willems JG, Kooi EJ, et al.
Complement C1q-C3-associated synaptic changes in
multiple sclerosis hippocampus. Ann Neurol 2015;
77: 1007–1026.

32. Jafari M, Schumacher AM, Snaidero N, et al.
Phagocyte-mediated synapse removal in cortical
neuroinflammation is promoted by local calcium
accumulation. Nat Neurosci 2021; 24: 355–367.

33. Schoonheim MM, Pinter D, Prouskas SE, et al.
Disability in multiple sclerosis is related to thalamic
connectivity and cortical network atrophy. Mult Scler
J 2022; 28: 61–70.

34. Schoonheim MM, Hulst HE, Brandt RB, et al.
Thalamus structure and function determine severity of
cognitive impairment in multiple sclerosis. Neurology
2015; 84: 776–783.

35. Calabrese M, De Stefano N, Atzori M, et al.
Extensive cortical inflammation is associated with
epilepsy in multiple sclerosis. J Neuro 2008; 255:
581–586.